Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.

Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY.

Ann Intern Med. 2019 Nov 5. doi: 10.7326/M19-0322. [Epub ahead of print]

PMID:
31683314
2.

Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States.

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ.

Ann Am Thorac Soc. 2019 Nov 1. doi: 10.1513/AnnalsATS.201901-094OC. [Epub ahead of print]

PMID:
31672025
3.

New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.

Han D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, Dorrius MD, Rook M, Nackaerts K, Walter JE, Groen HJM, Vliegenthart R, de Koning HJ, Oudkerke M.

J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521-X. doi: 10.1016/j.jtho.2019.09.193. [Epub ahead of print]

PMID:
31606605
4.

A comparative modeling analysis of risk-based lung cancer screening strategies.

Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ.

J Natl Cancer Inst. 2019 Sep 30. pii: djz164. doi: 10.1093/jnci/djz164. [Epub ahead of print]

PMID:
31566216
5.

Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.

Toes-Zoutendijk E, Kooyker AI, Dekker E, Spaander MCW, Opstal-van Winden AWJ, Ramakers C, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, Nagtegaal ID, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I; Dutch National Colorectal Cancer Screening Working Group.

Clin Gastroenterol Hepatol. 2019 Aug 20. pii: S1542-3565(19)30896-1. doi: 10.1016/j.cgh.2019.08.021. [Epub ahead of print]

6.

All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study.

Heijnsdijk EAM, Csanádi M, Gini A, Ten Haaf K, Bendes R, Anttila A, Senore C, de Koning HJ.

Cancer Med. 2019 Oct;8(13):6127-6138. doi: 10.1002/cam4.2476. Epub 2019 Aug 18.

7.

Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study.

Alagoz O, Hajjar A, Chootipongchaivat S, van Ravesteyn NT, Yeh JM, Ergun MA, de Koning HJ, Chicoine B, Martin B.

J Gen Intern Med. 2019 Nov;34(11):2374-2381. doi: 10.1007/s11606-019-05182-5. Epub 2019 Aug 5.

PMID:
31385214
8.

The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.

Getaneh AM, Heijnsdijk EA, de Koning HJ.

Public Health Res Pract. 2019 Jul 31;29(2). pii: 2921912. doi: 10.17061/phrp2921912.

9.

Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort.

Van Ourti T, O'Donnell O, Koç H, Fracheboud J, de Koning HJ.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32584. [Epub ahead of print]

PMID:
31330046
10.

The future is prosperous.

de Koning HJ.

J Natl Cancer Inst. 2019 Jul 11. pii: djz139. doi: 10.1093/jnci/djz139. [Epub ahead of print] No abstract available.

PMID:
31292643
11.

The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks.

Priaulx J, Turnbull E, Heijnsdijk E, Csanádi M, Senore C, de Koning HJ, McKee M.

J Health Serv Res Policy. 2019 Jul 8:1355819619842314. doi: 10.1177/1355819619842314. [Epub ahead of print] No abstract available.

12.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.

Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.

Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

PMID:
31221620
13.

Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran.

Bostamzad P, Horwood AM, Schalij-Delfos NE, Boelaert K, de Koning HJ, Simonsz HJ.

Acta Ophthalmol. 2019 Jun 14. doi: 10.1111/aos.14144. [Epub ahead of print]

PMID:
31197950
14.

Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators.

de Carvalho TM, Heijnsdijk EAM, Coffeng L, de Koning HJ.

Med Decis Making. 2019 May;39(4):405-413. doi: 10.1177/0272989X19837631. Epub 2019 Jun 10.

PMID:
31179833
15.

The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, de Koning HJ.

Eur Urol. 2019 Sep;76(3):276-279. doi: 10.1016/j.eururo.2019.04.007. Epub 2019 Apr 26.

PMID:
31031050
16.

Informed decision-making based on a leaflet in the context of prostate cancer screening.

Dierks T, Heijnsdijk EAM, Korfage IJ, Roobol MJ, de Koning HJ.

Patient Educ Couns. 2019 Aug;102(8):1483-1489. doi: 10.1016/j.pec.2019.03.009. Epub 2019 Apr 13.

PMID:
31014933
17.

Impact of a cardiovascular disease risk screening result on preventive behaviour in asymptomatic participants of the ROBINSCA trial.

Denissen SJ, van der Aalst CM, Vonder M, Oudkerk M, de Koning HJ.

Eur J Prev Cardiol. 2019 Aug;26(12):1313-1322. doi: 10.1177/2047487319843396. Epub 2019 Apr 9.

PMID:
30966821
18.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
19.

Treatment capacity required for full-scale implementation of lung cancer screening in the United States.

Blom EF, Ten Haaf K, Arenberg DA, de Koning HJ.

Cancer. 2019 Jun 15;125(12):2039-2048. doi: 10.1002/cncr.32026. Epub 2019 Feb 27.

20.

Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program.

Toes-Zoutendijk E, Bonfrer JMG, Ramakers C, Thelen M, Spaander MCW, Dekker E, van der Meulen MP, Buskermolen M, van Vuuren AJ, Kuipers EJ, van Kemenade FJ, van Velthuysen MF, Thomeer MGJ, van Veldhuizen H, van Ballegooijen M, de Koning HJ, van Leerdam ME, Lansdorp-Vogelaar I.

Clin Chem. 2019 Mar;65(3):419-426. doi: 10.1373/clinchem.2018.294041. Epub 2019 Jan 16.

PMID:
30651228
21.

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.

Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2019 Mar;74(3):247-253. doi: 10.1136/thoraxjnl-2018-212152. Epub 2018 Dec 27.

PMID:
30591535
22.

Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.

Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, Nackaerts K, van Ooijen PMA, de Koning HJ, Vliegenthart R, Oudkerk M.

Lung Cancer. 2018 Nov;125:103-108. doi: 10.1016/j.lungcan.2018.05.007. Epub 2018 May 14.

23.

A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs.

Priaulx J, Csanádi M, de Koning HJ, McKee M.

Int J Health Plann Manage. 2019 Jan;34(1):e34-e45. doi: 10.1002/hpm.2697. Epub 2018 Oct 31.

PMID:
30378696
24.

Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.

Buskermolen M, Gini A, Naber SK, Toes-Zoutendijk E, de Koning HJ, Lansdorp-Vogelaar I.

Med Decis Making. 2018 Nov;38(8):917-929. doi: 10.1177/0272989X18806497. Epub 2018 Oct 20.

25.

A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries.

Turnbull E, Priaulx J, van Ravesteyn NT, Heinävaara S, Siljander I, Senore C, Segnan N, Vokó Z, Hagymásy J, Jarm K, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1198-1205. doi: 10.1016/j.healthpol.2018.08.003. Epub 2018 Aug 24.

PMID:
30195444
26.

The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study.

Matthijsse SM, Naber SK, Hontelez JAC, Bakker R, van Ballegooijen M, Lansdorp-Vogelaar I, de Kok IMCM, de Koning HJ, van Rosmalen J, de Vlas SJ.

PLoS One. 2018 Sep 4;13(9):e0202924. doi: 10.1371/journal.pone.0202924. eCollection 2018.

27.

Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST).

Priaulx J, de Koning HJ, de Kok IMCM, Széles G, McKee M.

Health Policy. 2018 Nov;122(11):1190-1197. doi: 10.1016/j.healthpol.2018.08.004. Epub 2018 Aug 27.

PMID:
30177278
28.

Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries.

Turnbull E, Priaulx J, de Kok IMCM, Lansdorp-Vogelaar I, Anttila A, Sarkeala T, Senore C, Segnan N, Csanádi M, Pitter J, Novak Mlakar D, Ivanus U, Veerus P, de Koning HJ, McKee M.

Health Policy. 2018 Nov;122(11):1206-1211. doi: 10.1016/j.healthpol.2018.08.005. Epub 2018 Aug 24.

PMID:
30170757
29.

Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME.

BJU Int. 2019 Feb;123(2):307-312. doi: 10.1111/bju.14502. Epub 2018 Aug 27.

30.

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA.

Lung Cancer. 2018 Jul;121:61-69. doi: 10.1016/j.lungcan.2018.05.008. Epub 2018 May 26.

PMID:
29858029
31.

New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial.

Walter JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, Thunnissen E, Schermann A, Groen HJM, van der Aalst CM, Nackaerts K, Vliegenthart R, de Koning HJ, Oudkerk M.

J Thorac Oncol. 2018 Sep;13(9):1410-1414. doi: 10.1016/j.jtho.2018.05.006. Epub 2018 Jul 12.

32.

Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts.

de Lange SV, Bakker MF, Monninkhof EM, Peeters PHM, de Koekkoek-Doll PK, Mann RM, Rutten MJCM, Bisschops RHC, Veltman J, Duvivier KM, Lobbes MBI, de Koning HJ, Karssemeijer N, Pijnappel RM, Veldhuis WB, van Gils CH.

Clin Radiol. 2018 Aug;73(8):759.e1-759.e9. doi: 10.1016/j.crad.2018.04.002. Epub 2018 Jun 18.

PMID:
29759590
33.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

34.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

35.

Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.

van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):54S-65S. doi: 10.1177/0272989X17711928.

36.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

37.

Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

van Ravesteyn NT, van den Broek JJ, Li X, Weedon-Fekjær H, Schechter CB, Alagoz O, Huang X, Weaver DL, Burnside ES, Punglia RS, de Koning HJ, Lee SJ.

Med Decis Making. 2018 Apr;38(1_suppl):126S-139S. doi: 10.1177/0272989X17729358.

38.

High-pitch versus sequential mode for coronary calcium in individuals with a high heart rate: Potential for dose reduction.

Vonder M, Vliegenthart R, Kaatee MA, van der Aalst CM, van Ooijen PMA, de Bock GH, Gratama JW, Kuijpers D, de Koning HJ, Oudkerk M.

J Cardiovasc Comput Tomogr. 2018 Jul - Aug;12(4):298-304. doi: 10.1016/j.jcct.2018.02.005. Epub 2018 Mar 1.

PMID:
29551663
39.

Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.

Sankatsing VDV, Fracheboud J, de Munck L, Broeders MJM, van Ravesteyn NT, Heijnsdijk EAM, Verbeek ALM, Otten JDM, Pijnappel RM, Siesling S, de Koning HJ; National Evaluation Team for Breast cancer screening, NETB.

BMC Cancer. 2018 Mar 5;18(1):256. doi: 10.1186/s12885-018-4122-2.

40.

Clinically detected non-aggressive lung cancers: implications for overdiagnosis and overtreatment in lung cancer screening.

Ten Haaf K, van der Aalst CM, de Koning HJ.

Thorax. 2018 May;73(5):407-408. doi: 10.1136/thoraxjnl-2017-211149. Epub 2018 Feb 9. No abstract available.

PMID:
29440512
41.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

42.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

43.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

44.

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Cancer. 2018 Feb 1;124(3):507-513. doi: 10.1002/cncr.31141. Epub 2017 Dec 12.

45.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

46.

Re: Think before you leap.

Han SS, Ten Haaf K, Hazelton WD, Jeon J, Meza R, Kong CY, Feuer EJ, de Koning HJ, Plevritis SK.

Int J Cancer. 2018 Apr 1;142(7):1507-1509. doi: 10.1002/ijc.31183. Epub 2017 Dec 28. No abstract available.

47.

Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening.

Heuvelmans MA, Walter JE, Vliegenthart R, van Ooijen PMA, De Bock GH, de Koning HJ, Oudkerk M.

Thorax. 2018 Aug;73(8):779-781. doi: 10.1136/thoraxjnl-2017-210770. Epub 2017 Oct 22.

PMID:
29056601
48.

Lung cancer screening and its continuous risk assessment.

de Koning HJ.

Lancet Oncol. 2017 Nov;18(11):1434-1436. doi: 10.1016/S1470-2045(17)30730-1. Epub 2017 Oct 18. No abstract available.

PMID:
29055737
49.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

50.

Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening.

Han D, Heuvelmans MA, Vliegenthart R, Rook M, Dorrius MD, de Jonge GJ, Walter JE, van Ooijen PMA, de Koning HJ, Oudkerk M.

Br J Radiol. 2018 Oct;91(1090):20170405. doi: 10.1259/bjr.20170405. Epub 2017 Nov 8.

Supplemental Content

Loading ...
Support Center